EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Immune vulnerabilities of mutant KRAS in pancreatic cancer

Noah C Cheng, Robert H Vonderheide

Trends in Cancer · 2023-11 · 9 (11) · 928-936

DOI: 10.1016/j.trecan.2023.07.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2023-11. Verfasst von Noah C Cheng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Pancreatic Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Lustgarten Foundation, Oregon Health and Science University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 40-year desire to target the mutant Kirsten rat sarcoma (KRAS) gene (mKRAS) therapeutically is being realized with more and more broadly applicable and tumor-specific small-molecule inhibitors. Immunologically, mKRAS has equal desirability as a target. Tumor KRAS signaling plays a large role in shaping the immunosuppressive nature of the tumor microenvironment, especially in pancreatic cancer, leaving mKRAS inhibitors with potentially powerful immune modulatory capabilities that could be exploited in immunological-oncological combinations. mKRAS is itself an immunological antigen, a 'shared neoepitope' linked to the oncogenic process, validated biochemically and immunologically. Novel approaches in the clinic are taking advantage of the fact that mKRAS peptides are naturally processed and presented in tumors by the major histocompatibility complex (MHC).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Pancreatic NeoplasmsHumansMutationSignal TransductionTumor Microenvironment

Stichwörter der Autor:innen

TCR therapiesimmune responseinhibitorsmutant KRASpancreatic cancervaccines

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: rhv@upenn.edu.

Förderung

  • NCI NIH HHS
  • Lustgarten Foundation
  • Oregon Health and Science University
  • Boston Children's Hospital
  • University of Pennsylvania
  • Parker Institute for Cancer Immunotherapy
  • National Cancer Institute

Zitieren

APA

Cheng, N. C., & Vonderheide, R. H. (2023). Immune vulnerabilities of mutant KRAS in pancreatic cancer. Trends in Cancer, 9(11), 928-936. https://doi.org/10.1016/j.trecan.2023.07.004

Vancouver

Cheng NC, Vonderheide RH. Immune vulnerabilities of mutant KRAS in pancreatic cancer. Trends in Cancer. 2023;9(11):928-936. doi:10.1016/j.trecan.2023.07.004

BibTeX
@article{Cheng2023,
  author = {Cheng, Noah C and Vonderheide, Robert H},
  title = {Immune vulnerabilities of mutant KRAS in pancreatic cancer},
  journal = {Trends in Cancer},
  year = {2023},
  volume = {9},
  number = {11},
  pages = {928--936},
  doi = {10.1016/j.trecan.2023.07.004}
}
Kostenlos starten →